• 6 min read
• Published on 27 August 2025
Hey! We are Nemo.
Nemo, short for Never Miss Out, is a mobile investment platform that delivers curated, data-driven investment ideas to your fingertips. It offers commission-free trading across stocks, ETFs, crypto, and CFDs, along with AI-powered tools, real-time market alerts, and themed stock collections called Nemes.
Download the App
Scan the QR code to download the Nemo app and start investing on Nemo today
published-on
Read article
published-on
Read article
published-on
Read article
published-on
Read article
published-on
Read article
View the full Basket:Oral Obesity Treatments: Beyond The Needle
Let’s be honest, who actually enjoys jabbing themselves with a needle every week? I certainly don’t. It seems that for all the fanfare around wonder drugs like Ozempic and Wegovy, the pharmaceutical world overlooked a rather basic human truth. A significant chunk of the population would rather not, thank you very much. This simple aversion, this "needle problem", has kept a multi-billion pound market artificially capped for years. But now, the dam looks set to break, and for investors, the resulting flood could be quite something.
View the full Basket:Oral Obesity Treatments: Beyond The Needle
The numbers are staggering. Over 650 million adults worldwide are classified as obese, yet only a tiny fraction are using the most effective treatments. Why? Because they come in a syringe. It’s inconvenient, it’s a bit unnerving, and for the 20-30% of adults with a genuine needle phobia, it’s a complete non-starter. This has created a massive, untapped reservoir of demand. The company that can offer the same results in a simple, easy-to-swallow pill isn't just improving a product, it's potentially unlocking a market of a completely different magnitude.
View the full Basket:Oral Obesity Treatments: Beyond The Needle
Enter Eli Lilly. Their recent trial results for an oral drug called orforglipron were not just good, they were a validation of the entire concept. They proved that a pill could indeed deliver weight loss results comparable to the injections that have dominated the headlines. To me, this was the moment the starting gun was fired on a new pharmaceutical arms race. Suddenly, every major player in the metabolic disease space had to sit up and take notice. The race was on, and the laggards risked being left in the dust.
View the full Basket:Oral Obesity Treatments: Beyond The Needle
Eli Lilly, of course, has the early lead. They’ve proven it can be done and have a deep pipeline to back it up. But you’d be a fool to count out the current king, Novo Nordisk. As the maker of Ozempic and Wegovy, the Danish giant has the most to lose, which also means it has the most incentive to innovate and defend its turf. They have the expertise and the war chest to be a formidable competitor. Then you have the smaller, more nimble biotech firms like Structure Therapeutics, which are entirely focused on cracking the oral GLP-1 code. It’s a classic David vs. Goliath setup, playing out across multiple fronts.
View the full Basket:Oral Obesity Treatments: Beyond The Needle
The investment case here seems wonderfully straightforward. It’s not just about one company stealing market share from another. It’s about fundamentally expanding the entire pie. A successful pill could bring millions of new patients into the fold, people who were never going to consider weekly injections. To me, the real opportunity lies in what you might call the Oral Obesity Treatments: Beyond The Needle revolution. Companies that get this right could see sustained growth as patient compliance improves and distribution becomes simpler and cheaper without the need for cold-chain storage.
Of course, this is pharmaceutical investing, not a savings account. The risks are very real. Developing these drugs is fiendishly complex. The human gut is designed to break down proteins, which is precisely what these medicines are, so getting them to work in pill form is a huge scientific hurdle. Beyond that, there’s the gauntlet of regulatory approval, which is never a given. And with so many companies piling in, the competition will be fierce, potentially squeezing margins for everyone involved. Still, for those with a healthy appetite for risk, this is one of the most compelling stories in healthcare today.
View the full Basket:Oral Obesity Treatments: Beyond The Needle
View the full Basket:Oral Obesity Treatments: Beyond The Needle
View the full Basket:Oral Obesity Treatments: Beyond The Needle
View the full Basket:Oral Obesity Treatments: Beyond The Needle
View the full Basket:Oral Obesity Treatments: Beyond The Needle
View the full Basket:Oral Obesity Treatments: Beyond The Needle
This article is marketing material and should not be construed as investment advice. No information set out in this article be considered, as advice, recommendation, offer, or a solicitation, to buy or sell any financial product, nor is it financial, investment, or trading advice. Any references to specific financial product or investment strategy are for illustrative / educational purposes only and subject to change without notice. It is the investor’s responsibility to evaluate any prospective investment, assess their own financial situation, and seek independent professional advice. Past performance is not indicative of future results. Please refer to our Risk Disclosure.
published-on
Read article
published-on
Read article
published-on
Read article
published-on
Read article
published-on
Read article